Cyclohexene

Cyclohexene

SCHEMBL704338

C1=CCCCC1.COC(=O)C1CC=CCC1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.43
MIF P14174 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
ESR2 Q92731 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 2/20 0.39
LMNA P02545 1/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.37
CHRNB2 P17787 2/20 0.35
CHRNA4 P43681 2/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA7 P36544 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91215 0.94 TDP1 (0.46) TDP1MIFALDH1A1MEN1MAPT
SCHEMBL9613490 0.94 TDP1 (0.46) TDP1MIFALDH1A1MEN1MAPT
SCHEMBL11982130 0.94 TDP1 (0.46) TDP1MIFALDH1A1MEN1MAPT
SCHEMBL4015650 0.93 SMN1; SMN2 (0.45) TDP1MIFALDH1A1MEN1MAPT
SCHEMBL4015654 0.93 SMN1; SMN2 (0.45) TDP1MIFALDH1A1MEN1MAPT
SCHEMBL25161948 0.85 SMN1; SMN2 (0.47) TDP1ALDH1A1MAPTHTTKMT2A
SCHEMBL4017926 0.85 SMN1; SMN2 (0.47) TDP1ALDH1A1MAPTHTTKMT2A
SCHEMBL4017923 0.85 SMN1; SMN2 (0.47) TDP1ALDH1A1MAPTHTTKMT2A
SCHEMBL5046323 0.84 TP53 (0.47) ALDH1A1MAPTSMN1; SMN2TP53CHRNB2
SCHEMBL637275 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118719136-A Catalyst for epoxidation of bicyclo-diene compound as well as preparation method and application thereof 清华大学 2024-10-01 CN disclosed
US-8124816-B2 Hydrogenation of esters with Ru/tetradentate ligands complexes FIRMENICH SA (CH) 2012-02-28 US disclosed
US-7989665-B2 Hydrogenation of esters with Ru/tetradentate ligands complexes FIRMENICH SA (CH) 2011-08-02 US disclosed
US-20100125144-A1 HYDROGENATION OF ESTERS WITH RU/TETRADENTATE LIGANDS COMPLEXES SAUDAN LIONEL 2010-05-20 US disclosed
US-20080071098-A1 Forming alcohols or diols; using coordination catalyst FIRMENICH SA (CH) 2008-03-20 US disclosed
EP-0847417-B1 COMPOSITIONS CONTAINING 1,3,5-TRIAZINE CARBAMATES AND EPOXY COMPOUNDS CYTEC TECH CORP (US) 2004-11-24 EP disclosed
EP-1242529-A1 FORMALDEHYDE FREE 1,3,5-TRIAZINE CARBAMATE CROSSLINKERS AND CURABLE COMPOSITIONS CONTAINING SAME CYTEC TECHNOLOGY CORP. (US) 2002-09-25 EP disclosed
WO-2001040368-A1 FORMALDEHYDE FREE 1,3,5-TRIAZINE CARBAMATE CROSSLINKERS AND CURABLE COMPOSITIONS CONTAINING SAME CYTEC TECHNOLOGY CORP. (US) 2001-06-07 WO disclosed
US-6130297-A CURABLE COATING MIXTURE TO FORM FILMS WITH HARDNESS,IMPACT AND SOLVENT RESISTANCE, SMOOTH LOW GLOSS FINISH CYTEC TECHNOLOGY CORP. (US) 2000-10-10 US disclosed
EP-0935635-A1 LIQUID CROSS-LINKER COMPOSITIONS CONTAINING 1,3,5-TRIAZINE CARBAMATE/AMINOPLAST RESIN MIXTURES Cytec Technology Corp. (US) 1999-08-18 EP disclosed
EP-0931104-A1 CROSSLINKER COMPOSITIONS AND LOW GLOSS EPOXY COATINGS THEREFROM Cytec Technology Corp. (US) 1999-07-28 EP disclosed
US-5925285-A CARBOXYLIC CROSSLINKING AGENTS FOR COATINGS WITH EPOXY GROUPS CYTEC TECHNOLOGY CORP. (US) 1999-07-20 US disclosed
US-5852133-A Curable compositions containing 1,3,5-triazine carbamates and epoxy compounds CYTEC TECHNOLOGY CORP. (US) 1998-12-22 US disclosed
EP-0847417-A1 COMPOSITIONS CONTAINING 1,3,5-TRIAZINE CARBAMATES AND EPOXY COMPOUNDS Cytec Technology Corp. (US) 1998-06-17 EP disclosed
WO-1998018856-A1 LIQUID CROSS-LINKER COMPOSITIONS CONTAINING 1,3,5-TRIAZINE CARBAMATE/AMINOPLAST RESIN MIXTURES CYTEC TECHNOLOGY CORP. (US) 1998-05-07 WO disclosed
WO-1998015587-A1 CROSSLINKER COMPOSITIONS AND LOW GLOSS EPOXY COATINGS THEREFROM CYTEC TECHNOLOGY CORP. (US) 1998-04-16 WO disclosed
WO-1997008235-A1 COMPOSITIONS CONTAINING 1,3,5-TRIAZINE CARBAMATES AND EPOXY COMPOUNDS CYTEC TECHNOLOGY CORP. (US) 1997-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080071098-A1 Forming alcohols or diols; using coordination catalyst ADH1C, ADH1A, ADH5 TDP1 3539/4885MIF 1664/4885ALDH1A1 366/4885
US-20100125144-A1 HYDROGENATION OF ESTERS WITH RU/TETRADENTATE LIGANDS COMPLEXES ADH5, ADH1C, ADH1A TDP1 4138/4885MIF 501/4885ALDH1A1 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.